Applied DNA Q2 FY2023 revenue falls 28% to $4.4M; identifies mRNA acquisition target

BNB PLUS CORP.

2023-Q2 EPS reported -$0.25 revenue$9,670,366

Total revenues $4.4M, down from $6.1M YoY; COVID-19 testing revenue declined $1.5M.
Operating loss $2.7M vs $2.2M prior year; Adjusted EBITDA -$2.1M vs -$1.6M.
Cash $12.3M as of March 31, 2023, down from $15.2M in December 2022.
Identified mRNA value chain acquisition target; expects closing by June 30, 2023.
Submitted PGx assay validation to NYSDOH; approval anticipated in coming months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BNB PLUS CORP. reported second quarter of fiscal 2023 ended March 31, 2023 results: revenue $4.4 million.

Period: second quarter of fiscal 2023 ended March 31, 2023
Revenue: $4.4 million
Result: reported results

Exact text from the filing

Total revenues were $4.4 million for the three-month period ended March 31, 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BNB PLUS CORP. filing history →

Source: SEC EDGAR

accession 0001104659-23-059126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.